Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Researchers Develop Animal Free Methods for Testing Chemical Compounds for Allergens

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
EU-funded research project developing in vitro (‘out of body’) test strategies to reduce or replace animal testing use gene expression analysis software.

As of march 2013 there is a ban in the European Union (EU) on animal testing of ingredients for cosmetics.

The ban applies to all new cosmetics and their ingredients sold in the EU, regardless of where in the world testing on animals was carried out.

The 27 EU countries have had a ban on such tests in place since 2009, but despite this, cosmetics firms were allowed to continue testing on animals for the most complex human health effects, such as toxicity which might lead to cancer. However, those tests now come under the ban too.

This controversy has resulted in research to produce new, animal free, testing methods for chemicals. One such research initiative involved was Sens-it-iv (, a large EU-funded research project dedicated to develop and optimize in vitro (‘out of body’) test strategies that could reduce or replace animal testing for sensitization studies.

In 2005, lead by Malin Lindstedt, at the Department of Immunotechnology at Lund University, Sweden, and professor Carl Borrebaeck, Vice Chancellor of Lund University and sub-coordinator of Sens-it-iv, Lindstedt’s group joined with Sens-it-iv.

At this time there were no animal free methods for testing chemical compounds for their potential to induce allergies on the market.

One of the key partners involved with the project was the European Centre for the Validation of Alternative Methods (ECVAM) at the Joint Research Centre in Ispra, Italy.

As a result of this co-operation, Lindstedts’ group in Lund has now developed a completely animal free method based on human cells grown in the lab.

Dr. Ann-Sofie Albrekt, the bioinformatician in the team, has done a substantial amount of the analyses for the Sens-it-iv project and the further development of the animal free assay, named GARD (Genomic Allergen Rapid Detection).

As an internationally-renowned centre for research and education, Lund University is highly regarded for its research in cutting-edge fields including nanotechnology, translational cancer research, and stem cell biology.

Dr. Albrekt is currently focusing on two key areas: looking for new biomarkers in cancer studies, as well as performing important research on allergens.

"Worldwide, more and more people are suffering from allergies, which means that this area has become an important health concern," says Dr. Albrekt. "As a scientist, I am interested to find out why otherwise harmless compounds can often elicit an adverse immune response in humans."

Making sense of important data
Dr. Albrekt is currently using sophisticated data analysis software, called Qlucore Omics Explorer, to help her to get the most value out of the data being produced by this research.

"Although gene expression studies are proving invaluable to the study of allergens, the amount of data that is produced by these experiments is enormous," she says. "As a result, it is impossible to derive any real biological meaning from these findings unless sophisticated data algorithms are used to help interpret this data effectively."

For this reason, most of the software that has been designed for use in this area has mainly focused on the ability to handle increasingly vast amounts of data, which means that the role of the scientist/researcher has been largely set aside.

As a result, a lot of data analysis has been passed on to bioinformaticians and biostatisticians. However, in most cases, this model has several drawbacks, since it is typically the scientists themselves who know the most about biology.

"In our studies, we are dealing with very large amounts of data, sometimes between 10 and 100 million data points, which we tend to view as graphics” says Dr. Albrekt. “With other software, these graphics would take a long time to appear, but with the latest data analysis tools, the information is presented instantly. As a result, we can be much more creative with our theories, as we can easily test any number of hypotheses in rapid succession."

With the freedom, speed and flexibility provided by this approach, it is now possible to evaluate and test a number of different scenarios and hypothesis in a very short time, and to fully understand the data being examined.

This technique makes it possible for researchers to combine very large amounts of data, and therefore to conduct analysis in ways that were simply not possible before.

The future
The latest technological advances in this area are making it much easier for researchers to compare the vast quantity of genomic data generated, to test different hypotheses, and to explore alternative scenarios within seconds.

Not only that, but the latest generation of data analysis software is also helping the scientists (biologists, MD, and so on) to regain control of the analysis and to realize the true potential of gene expression profiling.

According to Dr. Albrekt, her own research efforts will continue to focus on both the allergen studies, as well as on the ongoing cancer research within CREATE Health, which is a strategic centre for translational cancer research.

"In terms of the work we did in the Sens-it-iv project, I am very confident that our success in creating an animal free test system will significantly reduce the number of animals sacrificed for safety testing and as well as increasing the accuracy of the safety tests performed " she says. "This project will therefore be of substantial benefit to all European citizens, and that goal continues to motivate me to make new discoveries in this area."

The assay development work resulting in the GARD assay will be presented in the doctoral thesis defense of Henrik Johansson on June 5th at Lund University.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Qlucore, Nebion Collaborate
Partnership aims to address complementary use cases.
Friday, February 07, 2014
Qlucore Receives European Funding That will Benefit Personalized Medicine
Hepatitis C patients to benefit from European funding awarded to Qlucore.
Thursday, September 05, 2013
Visualising Complex Data Results from 100,000 Cancer Patients
For decades, biomedical scientists have tried to develop a diagnostic tool for the early stages of cancer.
Wednesday, December 12, 2012
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
Unlocking the Secrets of Complex Genetic Data
A new approach to data analysis is helping researchers at Cincinnati Children's Hospital Medical Center to unravel the mysteries of human disease, says Carl-Johan Ivarsson, President of Qlucore.
Monday, March 19, 2012
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos